<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03555448</url>
  </required_header>
  <id_info>
    <org_study_id>201803162</org_study_id>
    <nct_id>NCT03555448</nct_id>
  </id_info>
  <brief_title>Once Daily Immunosuppression Regimen</brief_title>
  <official_title>Once a Day Immunosuppression Regimen: Outcomes and Compliance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Veloxis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to determine whether an immunosuppressive maintenance
      regimen of Envarsus/azathioprine compared to a tacrolimus/ mycophenolic acid regimen is
      associated with better compliance, tolerability, and lower biopsy proven rejection.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 4, 2018</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Compliance and tolerability of medication regimen at 3 and 12 months</measure>
    <time_frame>3 months and 12 months post transplant</time_frame>
    <description>BAASIS Survey</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Self-recorded Compliance and tolerability of medication regimen at 3 and 12 months</measure>
    <time_frame>3 months and 12 months post transplant</time_frame>
    <description>Pill Manager (personal medication record keeping for those who participants who choose to use this method of recording their self-administered medication)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite endpoint measurement</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of Biopsy proven Acute Rejection, graft loss, death, Lost to follow-up at 12 months.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Kidney Transplant; Complications</condition>
  <arm_group>
    <arm_group_label>Once daily regimen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Once daily medication regimen (Envarsus and azathioprine)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Twice daily regimen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Twice daily medication regimen (Tacrolimus and mycophenolic acid)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Once daily immunosuppression regimen</intervention_name>
    <description>Intervention focuses on the type of regimen, in this case the intervention arm will receive a once daily regimen for immunosuppression compared to the twice daily regimen.</description>
    <arm_group_label>Once daily regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Twice daily immunosuppression regimen</intervention_name>
    <description>This is the arm which we are designating the standard, which will be the comparison to the active drug arm.</description>
    <arm_group_label>Twice daily regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;/= 18 years old

          -  Kidney transplant recipient

          -  Thymoglobulin induction

        Exclusion Criteria:

          -  Non-renal organ transplant

          -  Combined organ transplant

          -  Inability to receive Envarsus after transplant

          -  Discharged to acute care facility after transplant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rowena Delos Santos</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rowena Delos Santos, MD</last_name>
    <phone>314-362-8351</phone>
    <email>delossantos@wustl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tarek Alhamad, MD</last_name>
    <phone>314-362-8351</phone>
    <email>talhamad@wustl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rowena Delos Santos, MD</last_name>
      <phone>314-362-8351</phone>
    </contact>
    <contact_backup>
      <last_name>Tarek Alhamad, MD</last_name>
      <phone>314-362-8351</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Budde K, Bunnapradist S, Grinyo JM, Ciechanowski K, Denny JE, Silva HT, Rostaing L; Envarsus study group. Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: one-year results of Phase III, double-blind, randomized trial. Am J Transplant. 2014 Dec;14(12):2796-806. doi: 10.1111/ajt.12955. Epub 2014 Oct 2.</citation>
    <PMID>25278376</PMID>
  </reference>
  <reference>
    <citation>Bunnapradist S, Ciechanowski K, West-Thielke P, Mulgaonkar S, Rostaing L, Vasudev B, Budde K; MELT investigators. Conversion from twice-daily tacrolimus to once-daily extended release tacrolimus (LCPT): the phase III randomized MELT trial. Am J Transplant. 2013 Mar;13(3):760-9. doi: 10.1111/ajt.12035. Epub 2012 Dec 21.</citation>
    <PMID>23279614</PMID>
  </reference>
  <reference>
    <citation>Jamieson NJ, Hanson CS, Josephson MA, Gordon EJ, Craig JC, Halleck F, Budde K, Tong A. Motivations, Challenges, and Attitudes to Self-management in Kidney Transplant Recipients: A Systematic Review of Qualitative Studies. Am J Kidney Dis. 2016 Mar;67(3):461-78. doi: 10.1053/j.ajkd.2015.07.030. Epub 2015 Sep 11. Review.</citation>
    <PMID>26372087</PMID>
  </reference>
  <reference>
    <citation>Laliberté F, Nelson WW, Lefebvre P, Schein JR, Rondeau-Leclaire J, Duh MS. Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients. Adv Ther. 2012 Aug;29(8):675-90. doi: 10.1007/s12325-012-0040-x. Epub 2012 Aug 15.</citation>
    <PMID>22898791</PMID>
  </reference>
  <reference>
    <citation>Rostaing L, Bunnapradist S, Grinyó JM, Ciechanowski K, Denny JE, Silva HT Jr, Budde K; Envarsus Study Group. Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial. Am J Kidney Dis. 2016 Apr;67(4):648-59. doi: 10.1053/j.ajkd.2015.10.024. Epub 2015 Dec 22.</citation>
    <PMID>26717860</PMID>
  </reference>
  <reference>
    <citation>Vrijens B, Heidbuchel H. Non-vitamin K antagonist oral anticoagulants: considerations on once- vs. twice-daily regimens and their potential impact on medication adherence. Europace. 2015 Apr;17(4):514-23. doi: 10.1093/europace/euu311. Epub 2015 Feb 17. Review.</citation>
    <PMID>25694538</PMID>
  </reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>May 17, 2018</study_first_submitted>
  <study_first_submitted_qc>May 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 13, 2018</study_first_posted>
  <last_update_submitted>December 30, 2019</last_update_submitted>
  <last_update_submitted_qc>December 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunosuppression</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

